Envoy MedicalCOCH
COCH
About: Envoy Medical Inc is a hearing health company focused on providing innovative medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life.
Employees: 34
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
18% more capital invested
Capital invested by funds: $2.82M [Q2] → $3.33M (+$513K) [Q3]
0.82% less ownership
Funds ownership: 6.09% [Q2] → 5.27% (-0.82%) [Q3]
10% less funds holding
Funds holding: 20 [Q2] → 18 (-2) [Q3]
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9
445%
upside
Avg. target
$9
445%
upside
High target
$9
445%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo 38% 1-year accuracy 28 / 73 met price target | 445%upside $9 | Buy Maintained | 6 Dec 2024 |
Brookline Capital Tyler Bussian 0% 1-year accuracy 0 / 3 met price target | 445%upside $9 | Buy Initiated | 14 Oct 2024 |
Financial journalist opinion
Neutral
Newsfile Corp
2 days ago
Envoy Medical Names Seven Investigational Sites for Participation in Its Pivotal Clinical Study
Initial patient enrollment anticipated during first quarter of 2025 White Bear Lake, Minnesota--(Newsfile Corp. - December 19, 2024) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company, today announces it has selected seven study sites for participation in its pivotal clinical trial to investigate its fully implanted Acclaim® cochlear implant (Acclaim CI). Initial patient enrollment is anticipated to begin during the first quarter of 2025.
Neutral
GlobeNewsWire
1 month ago
Envoy Medical Reports Third Quarter 2024 Results and Other Exciting Events
FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company FDA approval to begin pivotal trial of fully implanted cochlear implant and AMA approval of CPT codes for the Company's already FDA-approved fully implanted middle ear implant are two of the exciting developments for the growing company
Neutral
GlobeNewsWire
1 month ago
Envoy Medical's Fully Implanted Acclaim® Cochlear Implant Highlighted in Peer-Reviewed Publication
Study in Otology & Neurotology outlines early experiences and potential benefits of breakthrough fully implanted cochlear implant
Neutral
GlobeNewsWire
1 month ago
Envoy Medical Receives Another European Patent for its Modular Cochlear Implant System
WHITE BEAR LAKE, Minnesota, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announces that the European Patent Office has granted the Company Patent No. 3858425, titled,” Implantable Modular Cochlear Implant System with Communication System and Network.”
Neutral
GlobeNewsWire
1 month ago
Envoy Medical Receives FDA Approval To Initiate Pivotal Clinical Study for Breakthrough Hearing Device
The Acclaim® Fully Implanted Cochlear Implant is differentiated from existing cochlear implants and may offer new option for hearing loss patients
Neutral
GlobeNewsWire
1 month ago
Envoy Medical to Present at the LD Micro Main Event XVII
WHITE BEAR LAKE, Minnesota, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Envoy Medical®, Inc. (“Envoy Medical”) (NASDAQ: “COCH”), a hearing health company focused on fully implanted hearing systems, today announced that David R. Wells, Chief Financial Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.
Neutral
GlobeNewsWire
2 months ago
Major Envoy Medical Investor Glen Taylor Discusses How Apple's AirPods Pro 2 Hearing Aid Announcement is a Potentially Positive Development for the Company
During “The Claman Countdown,” the billionaire investor and entrepreneur noted how hearing aid modes in next-gen wireless earbuds can work with Envoy Medical's fully implanted hearing devices
Neutral
GlobeNewsWire
3 months ago
Envoy Medical Awarded Patent for Recharge System used with Implantable Battery
Growing Portfolio of Patents Further Advances the Company's Mission to Develop Fully Implanted Devices for Those Suffering from Significant Hearing Loss
Positive
Benzinga
3 months ago
Hyliion Holdings And 2 Other Stocks Under $5 Executives Are Buying
The Dow Jones index closed higher by more than 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
Neutral
GlobeNewsWire
4 months ago
Envoy Medical Reports Second Quarter 2024 Results and Provides Business Update
Company continues to make significant progress towards disrupting the existing cochlear implant industry with its investigational, breakthrough fully implanted Acclaim ® cochlear implant; Maintains goal of starting Pivotal Clinical Trial by end of the year
Charts implemented using Lightweight Charts™